Displaying 66 (all) recruiting clinical trials.
-
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
In this study, all patients will start with the same treatment using two drugs called topotecan and cyclophosphamide in the first cycle. After that, patents ...
Phase
Interventional
-
A Randomized Open-label Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-na ve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)
This is a Phase 2 study testing two different medicines to treat a blood cancer called GCB DLBCL(diffuse large B-cell lymhoma). Zilovertamab Vedotin (an ...
Phase
Interventional
-
A Randomised Open-Label Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1 BRCA2 or PALB2 Mutations and Hormone Receptor Positive HER2-Negative (IHC 0 1+ 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
This study is testing how well a new medicine, saruparib (AZD5305), works when combined with camizestrant compared to other common treatments for advanced breast cancer ...
Phase
Interventional
-
Global Phase 3 Randomized Open-Label Study to Evaluate Efficacy & Safety of Firmonertinib Comp.w/ Osimertinib or Afatinib as 1st line Treat. in Pts. w/ Locally Advanced or Metastatic NSCLC with EGFR PACC Uncommon Mutations (Alpacca)
This is a Phase 3 study testing the safety and effectiveness of the new medicine firmonertinib (an EGFR-tyrosine kinase inhibitor) and comparing it with standard ...
Phase
Interventional
-
A Phase 3 Randomized Double-blind Placebo-controlled Study of Pasritamig (JNJ-78278343) a T-cell-redirecting Agent Targeting Human Kallikrein 2 + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for ...Phase
Interventional
-
An Open-Label Randomized Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy VS Surgery and Adjuvant Therapy in Clinical Stage IIIB/C/D Melanoma Patients
The primary objective of the study is to demonstrate that a neoadjuvant Daromun treatment followed by surgery and adjuvant therapy improves in a statistically significant ...Phase
Interventional
-
AREN2231: Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
This phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most ...Phase
Interventional
-
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant HR+ HER2- Locally Advanced or Metastatic Breast Cancer
This is a Phase 3 study testing whether the study medicine RLY-2608 (selective inhibitors of PI3Ka) along with fulvestrant (standard hormone therapy) is more effective ...
Phase
Interventional
-
NRG-GI011 A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)
NRG-GI011, A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)Phase
Interventional
-
A Phase 3 Randomized Open-Label Multicenter Study of Amivantamab in Addition to Carboplatin and Pembro Compared to SOC Platinum and Pembro and 5-FU in Participants with Treatment-Na ve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Amivantamab (also known as RYBREVANT® [IV formulation] or JNJ-61186372) is a fully human IgG1-based bispecific antibody directed against both EGFR and MET and is approved ...Phase
Interventional
